LLY-284
Nëmme fir wëssenschaftlech Fuerschung, net fir Patienten.
Produit Detailer
Produit Tags
| Pak Gréisst | Disponibilitéit | Präis (USD) |
| 0, 1g | Op Stock | 350 |
| 0,5g vun | Op Stock | 750 |
| 1G | Op Stock | 910 |
Chemeschen Numm:
7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(5S)-5-C-phenyl-β-D-ribofuranosyl]-
SMILES Code:
O[C@H]1[C@H](N2C3C(=C(N=CN=3)N)C=C2)O[C@]([H])([C@@H](O) C2C=CC=CC=2)[C@H]1O
InChi Code:
InChI=1S/C17H18N4O4/c18-15-10-6-7-21(16(10)20-8-19-15)17-13(24)12(23)14(25-17)1 1(22)9-4-2-1-3-5-9/h1-8,11-14,17,22-24H,(H2,18,19,20)/t11-,12-,13+ ,14+,17+/m0/s1
InChi Schlëssel:
WWOOWAHTEXIWBO-CNUKPYSBSA-N
Schlësselwuert:
2226515-75-7; CAS: 2226515-75-7; CAS: 2226515-75-7; LLY-284; LLY 284; LLY 284
Solubilitéit:
Lagerung:
Beschreiwung:
LLY-283 ass en effektiven Inhibitor vu PRMT5.
Zil: PRMT5
![3-chlor-2-(10-fluor-8-(prop-1-yn-1-yl)-1,2,3,4,12,12a-hexahydro-6H-benzo[f]pyrazino[2,1 -c][1,4]oxazepin-9-yl)phenol](http://www.caerulumpharm.com/uploads/20240722105749.jpg)
![1H-Pyrazolo[3,4-d]pyrimidin, 6-chlor-1-[[4-[1-(1-methylethyl)-4-(trifluormethyl)-1H-imidazol-2-yl]phenyl]methyl]-](http://www.caerulumpharm.com/uploads/20240603134133.jpg)
![4H-1,3-Dioxolo[4,5-c]pyrrol-4-Carboxylsäure, tetrahydro-2,2-dimethyl-6-oxo-, (3aS,4S,6aS)-](http://www.caerulumpharm.com/uploads/20241023143839.jpg)
